A Short Treatment With an Antibody to Sclerostin Can Inhibit Bone Loss in an Ongoing Model of Colitis
Year: 2009
Type: article
DOI: 10.1359/jbmr.090403
Institution: UCB Pharma (United Kingdom)
Language: English
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Amgen, UCB Pharma
OpenAlex ID: W2029361003
